? Bristol Myers Squibb announced a $14 billion cash acquisition of Karuna Therapeutics, with Karuna’s shares surging over 47% and Bristol’s rising more than 2%. The move aims to bolster Bristol Myers’ drug pipeline, especially following a dip in demand for its blood cancer drug Revlimid.
? The acquisition focuses on expanding Bristol Myers’ presence in the neuroscience field, with Karuna’s lead asset, KarXT, an antipsychotic expected to treat schizophrenia by late 2024 and potentially Alzheimer’s disease psychosis and a form of bipolar disorder.
? Both companies’ boards unanimously approved the deal, expected to close in the first half of 2024, marking a significant stride in treatment advancements for neurological and psychiatric conditions. |